Treadwell-HPK1-inhibitor-IND-Approval

Jun 2, 2020

Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Study of HPK1 Inhibitor, CFI-402411

©2020 Treadwell Therapeutics
Terms of Use / Privacy Policy
Site by D&CO
New York Office
411 Lafayette Street, 6th Floor New York, New York, USA 10003